drugset / Trial / NCT03555071

A Phase 3 Lot-consistency Clinical Trial of Live Attenuated Varicella Vaccine

NCT03555071

Phase 3 Completed 1197 enrolled Sinovac (Dalian) Vaccine Technology Co., Ltd.
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to evaluate consistency, immunogenicity and safety of live attenuated varicella vaccines manufactured at commercialized scale in aged 1-3 years children.

Timeline

Start
2014-04-07
Primary completion
2017-05-20
Completion
2017-09-14

Drugs

EvaluationDrugModalityDoseRoute
Comparator Live Attenuated Varicella Vaccine Vaccine 0.5 ml Subcutaneous

Indications